Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
05/2008
05/28/2008CN100390153C Intermediate for producing novel pyrazine derivatives
05/28/2008CN100390151C 1-N-phenylamino-1h-imidazole derivatives as aromatase inhibitors
05/28/2008CN100390149C Indazole derivatives
05/28/2008CN100390148C Method for the treatment of malignant tumours
05/28/2008CN100390145C Novel crystalline forms of 4-[4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]-1-hydroxybutyl]-a, a-dimethylbenzene acetic acid and its hydrochloride
05/28/2008CN100390143C Synthesis of oxygen-substituted benzocycloheptenes, used as valuable intermediate products for producing tissue-selective oestrogens
05/28/2008CN100390136C Abiotic heparin antagonists
05/28/2008CN100390135C Novel derivatives of dicarboxylic acid having pharmaceutical properties
05/28/2008CN100390134C Compositions for treating acne comprising phytandiol amine
05/28/2008CN100390131C Unsaturated 1-amino-alkylcyclohexane NMDA, 5HT3 and neuronal nicotinic receptor antagonists
05/28/2008CN100389830C Medicinal composition for treating high blood pressure
05/28/2008CN100389829C Identification method of compound for inhibiting tumour injury and medicinal compositions containing said compound
05/28/2008CN100389828C Medicines comprising Rho kinase inhibitor
05/28/2008CN100389819C Chinese-medicine for treating cataracta ophthalmopathy
05/28/2008CN100389798C Litchi peel extract, its preparation method and purposes
05/28/2008CN100389792C Pharmaceutical composition for treating nose disease and its preparation method
05/28/2008CN100389791C Eye drops and preparation method thereof
05/28/2008CN100389790C Preparing method of medicine for treating burns or scald
05/28/2008CN100389787C Chinese-western medicine composition for treating hepatitis
05/28/2008CN100389779C Medicine composition used for cleaning intestinal tract
05/28/2008CN100389778C Lipase activity inhibitor containing high-molecular weight polyphenol fraction, tea extract and process for producing the same
05/28/2008CN100389777C Moderate molecular weighted chondroitin sulfate injection and its preparing process
05/28/2008CN100389776C Use of CM101 in preparing medicine
05/28/2008CN100389775C Total epimeddium flavone tablet and its use in preparation of medicine for relaying immunity decrepitudation
05/28/2008CN100389774C Medicinal composition for treating diabetes and its preparation method
05/28/2008CN100389773C Novel helicobacter pylori-binding substances and use thereof
05/28/2008CN100389772C Use of zolendronate for mfg. medicament for treatment of bone metabolism diseases
05/28/2008CN100389771C Use of composition comprising Formoterol and Budesonide for prevention or treatment of acute condition of asthma
05/28/2008CN100389770C Transparent eye drops containing latanoprost
05/28/2008CN100389769C Compound water soluble preparation of domperidone and crotamiton and production thereof
05/28/2008CN100389768C Milrinone composition for injection and its preparation process
05/28/2008CN100389767C Injectable stable pharmaceutical composition containing active ingredient silibinin and its salt
05/28/2008CN100389766C Pharmaceutical use of dihydro myricetin
05/28/2008CN100389765C Composition for the prevention of osteoporosis comprising a combination of isoflavones and polyunsaturated fatty acids
05/28/2008CN100389764C Freeze dried composition containing thiopronin and its preparation method
05/28/2008CN100389763C Lactic acid , glycerin formulation for female vagina acidity, humidity improvement
05/28/2008CN100389762C Use of 5-hydroxy-1-(4- hydroxyphenyl)-7-phynyl-3-heptanone
05/28/2008CN100389761C Use of 7-(4- hydroxyphenyl)-1-phynyl-4-alkene-3-heptanone
05/28/2008CN100389760C Enteric coated drop pills of garlicin, and preparation method
05/28/2008CN100389759C Use of ¿C(4-hydroxy-3-methoxyphenyl)-7-(4- hydroxyphenyl)-3,5-dihydroxy heptane
05/28/2008CN100389758C Preparation method of nonoxinol foamable composition and its quality control method
05/28/2008CN100389757C Guaiamar dripping pill
05/28/2008CN100389755C Compositions and methods for mucosal delivery
05/28/2008CN100389751C Swallow tablet comprising paracetamol
05/28/2008CN100389750C Pharmaceutical composition with improved solubility and fluidity
05/28/2008CN100389748C Chemotherapeutic emulsion for treating rectum cancer
05/28/2008CN100389741C A method for preparing a medical solution for the manufacture of a medicament for peritoneal dialysis
05/28/2008CN100389740C A method for preparing a medical solution for the manufacture of a medicament for peritoneal dialysis
05/27/2008US7378557 method for making isolongifolenone involving reaction (-)-isolongifolene with chromium hexacarbonyl and t-butyl hydroperoxide. Also the use of isolongifolenone to repel arthropods by treating an object or area with an arthropod repelling effective amount of isolongifolenone
05/27/2008US7378552 Monoamine re-uptake inhibitors and methods relating thereto
05/27/2008US7378551 gelling agent having a high ability of gelling an oily base which is capable of giving a gel composition having a strong gel strength and a good transparency, a gel composition having a strong gel strength and a good transparency, an external composition having a good feel upon use, a cosmetic
05/27/2008US7378535 Production of furanones
05/27/2008US7378534 Anti-first-pass effect compounds
05/27/2008US7378532 Anticancer agents; such as succinic acid mono-[5-(1-benzyl-1H-indazol-3-yl)-furan-2-ylmethyl]ester, sodium salt; inhibit cancer cell growth
05/27/2008US7378529 Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4
05/27/2008US7378526 Cholinergic ligands at the nicotinic acetylcholine receptors; diseases related to the cholinergic system; neurodegenerative disorders; pain; antiinflammatory; diagnostic or monitoring tools using labelled forms; 3-Phenyletynyl-quinuclidin-2-ene
05/27/2008US7378524 e.g., 6-chloro-2-methyl-4-(N-(2-(N-(p-methoxyphenylsulfonyl)-N-(2-(2,5-dimethoxy-4-nitroanilinocarbonyl)ethyl)amino)ethyl)amino)quinoline; used to treat inflammatory and immune diseases by binding to CXCR3 receptors.
05/27/2008US7378522 Such as 6-(4-Acetamidophenoxy)-5-(N-benzyl-N-methylaminomethyl)-1-(2',6'-difluorobenzyl)-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid-ethyl ester; rapid effectiveness, bioavailability; low cost, simple synthesis
05/27/2008US7378519 enantiomerically pure 1S,2S-tramadol hydrochloride by dissolving topiramate and tramadol hydrochloride; cooling; crystallization; filtration; separating the 1S,2S-tramadol hydrochloride from the mother liquor by chromatography or crystallization
05/27/2008US7378518 Vascular conditions such as atherosclerosis, hypercholesterolemia, diabetes, obesity, stroke, demyelination; lowering plasma levels of sterols and/or stanols
05/27/2008US7378490 a cyclic dodecapeptide containing Arg, Asp, Ala, Glu, Ser, Gly, Ala; cyclic peptides serve as antigens for producing a neutralizing antibody capable of neutralizing HIV-1 virus infection via the second receptors called CXCR4 and CCR5
05/27/2008US7378485 A compound containing a polyamide backbone bearing a plurality of ligands that are individually bound to aza nitrogen atoms loacted within the backbone and atleast one ligand is a nucleobase, a DNA intercalator or nucleobase binder
05/27/2008US7378448 Diphenylether amide derivatives as opioid receptor antagonists
05/27/2008US7378446 1-((4,14-(Dioxo),5-(1-hydroxy,1,2-dicarboxyethyl)),3-azaoctadec-6-enyl-),4-(phenoxy)benzene derivatives and salts ; extremely potent replication inhibitory activity against the hepatitis C virus (HCV); chronic hepatitis, cirrhosis and liver cancer; mild cytotoxicity in vitro; prophylaxis; prodrugs
05/27/2008US7378445 Treatment of prostate cancer
05/27/2008US7378444 Antiinflammatory agents; cardiovascular disorders; vision disorders; skin disorders; central nervous system disorders; antiarthritic agents
05/27/2008US7378443 Fatty acid analogues for the treatment of cancer
05/27/2008US7378442 Chemical entities with multiple modes of anti-inflammatory action
05/27/2008US7378441 Resistance-repellent retroviral protease inhibitors
05/27/2008US7378440 Antidiabetic agents; therapy for insulin resistance
05/27/2008US7378439 Process for the preparation of 4-(2-dipropylaminoethyl)-1,3-dihydro-2H-indol-2-one hydrochloride
05/27/2008US7378438 Asthma; side effect reduction; converting SH groups to SNO groups of N-benzylphthalimide usingHCl and NaNO2; epoxide or thioepoxid of N-benzylphthalimide; amination; 5-{2-[(1-Yloxyl-2,2,5,5-tetramethyl-pyrrolidin-3-ylmethyl)-amino]-1-S-nitroso-ethyl}-1,1,3,3-tetramethylisoindolin-2-yloxyl, hydrochloride
05/27/2008US7378437 Use for the diabetes treatment of compounds or salts thereof, having the following general formula (I): A-(B)b0-(C)c0-NO2 wherein A contains the radical of a drug having an antiiflammatory or analgesic activity, B is a bivalen: linking
05/27/2008US7378436 Substituted N-[pyrrolidin-3-yl] benzamides or naphthamides; serotonin and noradrenaline receptor antagonists; urinary incontinence; arylation of the amino pyrrolidine with a carboxylic acid or acyl halide and then deprotecting
05/27/2008US7378435 High affinity and selectivity for GABA A alpha 5 receptor binding sites; cognitive enhancer; Alzheimer's disease; 3-(5-methyl-3-phenyl-isoxazole-4-carbonyl)-1H-indole-6-carboxylic acid prop-2-ynylamide
05/27/2008US7378434 Administering metaxalone to treat a musculoskeletal condition of a human along with an inhibitor or inducer of CYP1A2; include instructions that this dosage can affect the patient's plasma concentration, bioavailability, safety, efficacy, or a combination; monitoring plasma concentration of metaxalone
05/27/2008US7378433 N-[4-(heteroarylmethyl)phenyl]-heteroarylamines
05/27/2008US7378431 Amide derivatives as NMDA receptor antagonists
05/27/2008US7378430 inhibitors of cGMP PDE, especially Type 5; erectile dysfunction and sexual disorders; 6-Bromo-N-[(3-chloro-methoxyphenyl)methyl]-2-(2-pyridinyl)-4-quinolinamine
05/27/2008US7378428 phosphodiesterase inhibitors; (Z)-2-(7-bromomethyl-3,3-dimethyl-3,4-dihydro-(2H)-isoquinolin-1-ylidene)-1-(adamantan-1-yl)ethan-1-one; graft versus host disease, osteoporosis, bone fracture, restenosis, arteriosclerosis, obesity, ischemic reperfusion injury, depression, allergies, transplant rejection
05/27/2008US7378427 Processes for preparing 6-alkyl-5-arylsulfonyl-dihydrophenanthridines
05/27/2008US7378426 Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
05/27/2008US7378425 For preventing, treating and/or improving a disease against which a sigma receptor binding action and/or an acetylcholinesterase inhibitory action is efficacious
05/27/2008US7378424 Derivatives of pyrimido[6, 1-A]isoquinolin-4-one
05/27/2008US7378423 Antiproliferative, anticancer, antitumor agents; rheumatism; N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]-phenyl}-acetamide; a p15, and/or a protein inducing action, and/or an MEK inhibitory action; side effect reduction
05/27/2008US7378422 Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
05/27/2008US7378421 Chromenone derivatives
05/27/2008US7378420 4-[(2,4-dichloro-phenyl)-phenyl-methyl]-piperazine-1-carboxylic acid benzhydryl-amide; conjugated to polyethylene glycol; analgesic, antidiabetic and anticarcinogenic agent, antidepressant, anxiolytic agent
05/27/2008US7378419 3-{[(5,5a,8a,9)-9-(4-hydroxy-3,5-dimethoxyphenyl)-8-oxo-5,5a,6,8,8a,9-hexahydrofuro[3',4':6,7]naphtho[2,3-d][1,3]dioxol-5-yl]amino}-1-methyl-1H-pyrrole-2,5-dione; anticarcinogenic agent; inhibiting catalytic activity of topoisomerase II by stabilization of cleavable complex; better soluble and tolerated
05/27/2008US7378418 Azabicyclic heterocycles as cannabinoid receptor modulators
05/27/2008US7378417 Pyrazolo-pyrimidine derivatives
05/27/2008US7378416 3-((C3-8)cycloalkyl)-3,4-dihydro-benzo[e][1,3]oxazin-2-ones; counter-regulator of antiinflammatory effects of glucocorticoids with effect that normal activities of glucocorticoids to limit and suppress severity of inflammatory responses are inhibited by macriphage migration inhibitory factor (MIF)
05/27/2008US7378415 Benzoxazine and quinoxaline derivatives and uses thereof
05/27/2008US7378414 Viricides for infections caused by an RNA-containing virus; enzyme inhibitors for a hepatitis C virus (HCV) polymerase; inhibiting HCV viral replication; liver cirrhosis; e. g., 3-(1,1-dioxido-4H-1,2,4-benzothiadiazin-3-yl)-4-hydroxy-1,1-dipropyl-2(1H)-naphthalenone
05/27/2008US7378413 2-amino-3-(alkyl)-pyrimidone derivatives
05/27/2008US7378412 Pharmaceutical compounds
05/27/2008US7378411 Substituted thienopyrimidinones as a mitotic kinesin inhibitor
05/27/2008US7378410 3,4,5-trihydroxy-2-methoxy-8,8-dimethyl-non-enoic acid ((3S,6S)-6-azido-2-oxo-azepan-3-yl)-amide; less toxicity, better selectivity in killing cancer cells, minimal effect on normal healthy cells
05/27/2008US7378409 Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity
05/27/2008US7378408 Methods of treatment and formulations of cephalosporin